Literature DB >> 24435046

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Menachem Bitan1, Wensheng He, Mei-Jie Zhang, Hisham Abdel-Azim, Mouhab Fakhreddine Ayas, Bella Bielorai, Paul A Carpenter, Mitchell S Cairo, Miguel Angel Diaz, John T Horan, Sonata Jodele, Carrie L Kitko, Kirk R Schultz, Morris Kletzel, Kimberly A Kasow, Leslie E Lehmann, Parinda A Mehta, Nirali Shah, Michael A Pulsipher, Tim Prestidge, Adriana Seber, Shalini Shenoy, Ann E Woolfrey, Lolie C Yu, Stella M Davies.   

Abstract

The safety and efficacy of reduced-intensity conditioning (RIC) regimens for the treatment of pediatric acute myeloid leukemia is unknown. We compared the outcome of allogeneic hematopoietic cell transplantation in children with acute myeloid leukemia using RIC regimens with those receiving myeloablative-conditioning (MAC) regimens. A total of 180 patients were evaluated (39 with RIC and 141 with MAC regimens). Results of univariate and multivariate analysis showed no significant differences in the rates of acute and chronic graft-versus-host disease, leukemia-free, and overall survival between treatment groups. The 5-year probabilities of overall survival with RIC and MAC regimens were 45% and 48%, respectively (P = .99). Moreover, relapse rates were not higher with RIC compared with MAC regimens (39% vs 39%; P = .95), and recipients of MAC regimens were not at higher risk for transplant-related mortality compared with recipients of RIC regimens (16% vs 16%; P = .73). After carefully controlled analyses, we found that in this relatively modest study population, the data supported a role for RIC regimens for acute myeloid leukemia in children undergoing allogeneic hematopoietic cell transplantation. The data also provided justification for designing a carefully controlled randomized clinical trial that examines the efficacy of regimen intensity in this population.

Entities:  

Mesh:

Year:  2014        PMID: 24435046      PMCID: PMC3945869          DOI: 10.1182/blood-2013-10-535716

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

Review 2.  Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a European view.

Authors:  Ursula Creutzig; Dirk Reinhardt
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

Review 3.  Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view.

Authors:  Allen R Chen; Todd A Alonzo; William G Woods; Robert J Arceci
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

4.  Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.

Authors:  B L Scott; B M Sandmaier; B Storer; M B Maris; M L Sorror; D G Maloney; T R Chauncey; R Storb; H J Deeg
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

5.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

6.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Michael B Maris; Frédéric Baron; David G Maloney; Bart L Scott; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb
Journal:  J Clin Oncol       Date:  2007-08-27       Impact factor: 44.544

7.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

8.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

Authors:  Olle Ringdén; Myriam Labopin; Gerhard Ehninger; Dietger Niederwieser; Richard Olsson; Nadezda Basara; Juergen Finke; Rainer Schwerdtfeger; Matthias Eder; Donald Bunjes; Norbert-Claude Gorin; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.

Authors:  Michael A Pulsipher; Kenneth M Boucher; Donna Wall; Haydar Frangoul; Michel Duval; Rakesh K Goyal; Peter J Shaw; Ann E Haight; Michael Grimley; Stephan A Grupp; Morris Kletzel; Richard Kadota
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

View more
  19 in total

1.  Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Authors:  J R Passweg; M Labopin; J Cornelissen; L Volin; G Socié; A Huynh; R Tabrizi; D Wu; C Craddock; N Schaap; J Kuball; P Chevallier; J Y Cahn; D Blaise; A Ghavamzadeh; K Bilger; F Ciceri; C Schmid; S Giebel; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

2.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

3.  Effective Treatment of a Childhood Blastic Plasmacytoid Dendritic Cell Neoplasm with a Cutaneous Tumor Alone by Stem Cell Transplantation with Reduced Intensity Conditioning.

Authors:  Maiko Shimomura; Takaki Asano; Aya Furue; Mizuka Miki; Yasuhiko Sera; Hiroshi Kawaguchi; Kazuhiro Nakamura; Masao Kobayashi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-21       Impact factor: 0.900

4.  Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.

Authors:  X He; Q Wang; J Cen; H Qiu; A Sun; S Chen; D Wu
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

5.  Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.

Authors:  Martin G Sauer; Peter J Lang; Michael H Albert; Peter Bader; Ursula Creutzig; Matthias Eyrich; Johann Greil; Bernd Gruhn; Wolfgang Holter; Thomas Klingebiel; Bernhard Kremens; Heiko von der Leyen; Christine Mauz-Körholz; Roland Meisel; Kirsten Mischke; Ingo Müller; Charlotte M Niemeyer; Christina Peters; Christine Pohler; Dirk Reinhardt; Birgit Burkhardt; Paul G Schlegel; Ansgar S Schulz; Johanna Schrum; Petr Sedlacek; Brigitte Strahm; Wilhelm Woessmann; Rupert Handgretinger; Martin Zimmermann; Arndt Borkhardt
Journal:  Leukemia       Date:  2019-10-02       Impact factor: 11.528

6.  Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Authors:  Orly R Klein; Jessica Buddenbaum; Noah Tucker; Allen R Chen; Christopher J Gamper; David Loeb; Elias Zambidis; Nicolas J Llosa; Jeffrey S Huo; Nancy Robey; Mary Jo Holuba; Yvette L Kasamon; Shannon R McCurdy; Richard Ambinder; Javier Bolaños-Meade; Leo Luznik; Ephraim J Fuchs; Richard J Jones; Kenneth R Cooke; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-22       Impact factor: 5.742

7.  Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.

Authors:  Daisuke Tomizawa; Tomoyuki Watanabe; Ryoji Hanada; Keizo Horibe; Yasuo Horikoshi; Shotaro Iwamoto; Akitoshi Kinoshita; Hiroshi Moritake; Hideki Nakayama; Akira Shimada; Takashi Taga; Hiroyuki Takahashi; Akio Tawa; Kiminori Terui; Hiroki Hori; Yoshifumi Kawano; Atsushi Kikuta; Atsushi Manabe; Souichi Adachi
Journal:  Int J Hematol       Date:  2015-07-01       Impact factor: 2.490

8.  Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

Authors:  Matt S Zinter; Brent R Logan; Caitrin Fretham; Anil Sapru; Allistair Abraham; Mahmoud D Aljurf; Staci D Arnold; Andrew Artz; Jeffery J Auletta; Saurabh Chhabra; Edward Copelan; Christine Duncan; Robert P Gale; Eva Guinan; Peiman Hematti; Amy K Keating; David I Marks; Richard Olsson; Bipin N Savani; Celalettin Ustun; Kirsten M Williams; Marcelo C Pasquini; Christopher C Dvorak
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

9.  Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Authors:  N Bleyzac; D Cuzzubbo; C Rénard; N Garnier; V Dubois; C Domenech; M-P Goutagny; A Plesa; N Grardel; S Goutelle; A Janoly-Duménil; Y Bertrand
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

10.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Authors:  E Brissot; F Rialland; X Cahu; M Strullu; N Corradini; C Thomas; N Blin; X Rialland; E Thebaud; P Chevallier; P Moreau; N Milpied; J L Harousseau; F Mechinaud; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.